Product details

Share this page:
Please find below the full details of the product you clicked a link to view.
Thumbnail image for JBEE2-1CS1
Prize winner
Published by:
NeilsonJournals Publishing (2005)
 
in "Journal of Business Ethics Education"
Length:
14 pages
Data source:
Published sources

Abstract

This is the first of a two case series (JBEE2-1CS1 and JBEE2-1CS2). The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world's second largest pharmaceutical company, GlaxoSmithKline (GSK). GSK also became the world's leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK respond to these pressures? This article has been peer reviewed by the editorial board of the Journal of Business Ethics Education - JBEE.

Teaching and learning

This item is suitable for postgraduate and executive education courses.

Topics

Corporate social responsibility; Stakeholders; Pricing; Pharmaceutical industry; Access to medicines; Leadership; Developing countries

Setting

The events covered by this item took place in 2000.

Geographical setting

Region:
World/global

Featured company

Company name:
GlaxoSmithKline
Industry:
Pharmaceutical industry

Access this item

casecent.re/p/66061
View our pricing guide
or to see prices.

Awards, prizes & competitions

2006 - ecch European Case Awards - category winner

Reviews & usage